Triamcinolone Ketorolac (TriKe) Knee Trial (TriKe)
Osteoarthritis, Knee
About this trial
This is an interventional treatment trial for Osteoarthritis, Knee
Eligibility Criteria
Inclusion Criteria:
- Knee pain with diagnosis of osteoarthritis/osteoarthrosis
- Weight-bearing x-rays within the last year adequate to assess Kellgran-Lawrence OA stage
- Age > 21
- English proficiency sufficient to complete surveys
- Willing to complete follow-up surveys
Exclusion Criteria:
- Prior knee injection in last 3 months
- Knee surgery within the last year
- Contraindications to Cortisone, Ketorolac, or local anesthetic
- Uncontrolled diabetes
- Systemic steroid use in last 3 months
- BMI > 50
- Non-ambulatory
- Known kidney disease
- Current opioid use
Sites / Locations
- United Health Services Sports Medicine Department
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Triamcinolone acetonide - Ropivacaine - Normal Saline
Ketorolac - Ropivacaine - Normal Saline
Triamcinolone acetonide - Ketorolac - Ropivacaine
Subject would receive: Triamcinolone acetonide, 40 mg/mL. 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization
Subject would receive: Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL Saline 0.9% 1 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization
Subject would receive: Triamcinolone acetonide, 40 mg/mL Ketorolac 30 mg/mL, 1 mL Ropivacaine 0.2%, 2 mL for a total of 4 mL injected intraarticularly into affected knee/s at randomization